ABBVIE INC (1ABBV.MI) Stock Price & Overview
BIT:1ABBV • US00287Y1091
Current stock price
The current stock price of 1ABBV.MI is 180.75 EUR. Today 1ABBV.MI is up by 0.5%. In the past month the price increased by 12.97%.
1ABBV.MI Key Statistics
- Market Cap
- 319.703B
- P/E
- 21.31
- Fwd P/E
- 14.38
- EPS (TTM)
- 8.48
- Dividend Yield
- 3.31%
1ABBV.MI Stock Performance
1ABBV.MI Stock Chart
1ABBV.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1ABBV.MI.
1ABBV.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1ABBV.MI. While 1ABBV.MI belongs to the best of the industry regarding profitability, there are concerns on its financial health.
1ABBV.MI Earnings
On February 4, 2026 1ABBV.MI reported an EPS of 2.71 and a revenue of 16.62B. The company beat EPS expectations (0.18% surprise) and missed revenue expectations (-0.78% surprise).
1ABBV.MI Forecast & Estimates
39 analysts have analysed 1ABBV.MI and the average price target is 228.25 EUR. This implies a price increase of 26.28% is expected in the next year compared to the current price of 180.75.
For the next year, analysts expect an EPS growth of 48.29% and a revenue growth 10.03% for 1ABBV.MI
1ABBV.MI Groups
Sector & Classification
1ABBV.MI Financial Highlights
Over the last trailing twelve months 1ABBV.MI reported a non-GAAP Earnings per Share(EPS) of 8.48. The EPS decreased by -1.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.84% | ||
| ROA | 3.12% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
1ABBV.MI Ownership
1ABBV.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 31.06 | 44.565B | ||
| ARGX | ARGENX SE | 30.61 | 44.006B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.431B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| ABVX | ABIVAX SA | N/A | 7.961B | ||
| GLPG | GALAPAGOS NV | N/A | 1.638B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.342B | ||
| PHGN | PHARMING GROUP NV | 49.55 | 1.054B | ||
| PHARM | PHARMING GROUP NV | 49.15 | 1.05B | ||
| IVA | INVENTIVA SA | N/A | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1ABBV.MI
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Company Info
IPO: 2013-01-02
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 57000
Phone: 13023513367
ABBVIE INC / 1ABBV.MI FAQ
Can you describe the business of ABBVIE INC?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
What is the current price of 1ABBV stock?
The current stock price of 1ABBV.MI is 180.75 EUR. The price increased by 0.5% in the last trading session.
Does ABBVIE INC pay dividends?
ABBVIE INC (1ABBV.MI) has a dividend yield of 3.31%. The yearly dividend amount is currently 5.59.
What is the ChartMill technical and fundamental rating of 1ABBV stock?
1ABBV.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for 1ABBV.MI stock?
39 analysts have analysed 1ABBV.MI and the average price target is 228.25 EUR. This implies a price increase of 26.28% is expected in the next year compared to the current price of 180.75.
Can you provide the number of employees for ABBVIE INC?
ABBVIE INC (1ABBV.MI) currently has 57000 employees.